Meropenem and Piperacillin Plasma Concentrations During CRRT
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 135
- 试验地点
- 1
- 主要终点
- Plasma antibiotic concentrations at mid and end of dosing interval
研究概览
简要总结
This observational study reports meropenem and piperacillin plasma concentrations in patients treated with either antibiotic and simultaneous continuous renal replacement therapy (CRRT).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients treated in the study ICU and
- •simultaneous CRRT and antibiotic treatment with either meropenem or piperacillin-tazobactam.
排除标准
- 未提供
结局指标
主要结局
Plasma antibiotic concentrations at mid and end of dosing interval
时间窗: 1 week
The percentage of patients having a concentration above the highest MIC (minimal inhibitory concentration) breakpoint for pathogens considered susceptible for the antibiotic.
Relationships between plasma antibiotic concentrations and CRRT dose.
时间窗: 1 week
We will report the correlation between measured plasma concentrations of either antibiotic and the intensity of the CRRT treatment.
Influence of residual diuresis on the measured plasma antibiotic concentrations.
时间窗: 1 week
We will report the correlation between measured plasma concentrations of either antibiotic and residual diuresis.
次要结局
未报告次要终点
研究者
Johan Petersson
Senior ICU Consultant
Karolinska University Hospital